

## ***APOE/TOMM40* genetic loci, white matter hyperintensities, and cerebral microbleeds**

Donald M. Lyall<sup>1,2,3,4</sup>, Susana Muñoz Maniega<sup>1,2,5</sup>, Sarah E. Harris<sup>1,4</sup>, Mark E. Bastin<sup>1,2,5</sup>, Catherine Murray<sup>1,3</sup>, Michael W. Lutz<sup>6</sup>, Ann M. Saunders<sup>6</sup>, Allen D. Roses<sup>6,7</sup>, Maria del C. Valdés Hernández<sup>1,2,5</sup>, Natalie A. Royle<sup>1,2,5</sup>, John M. Starr<sup>1,8</sup>, David J. Porteous<sup>1,4</sup>, Ian J. Deary<sup>1,3</sup>, and Joanna M. Wardlaw<sup>1,2,5\*</sup>

**Background** Two markers of cerebral small vessel disease are white matter hyperintensities and cerebral microbleeds, which commonly occur in people with Alzheimer's disease.

**Aim and/or hypothesis** To test for independent associations between two Alzheimer's disease-susceptibility gene loci – *APOE*  $\epsilon$  and the *TOMM40* '523' poly-T repeat – and white matter hyperintensities/cerebral microbleed burden in community-dwelling older adults.

**Methods** Participants in the Lothian Birth Cohort 1936 underwent genotyping for *APOE*  $\epsilon$  and *TOMM40* 523, and detailed structural brain magnetic resonance imaging at a mean age of 72.70 years (standard deviation = 0.7; range = 71–74).

**Results** No significant effects of *APOE*  $\epsilon$  or *TOMM40* 523 genotypes on white matter hyperintensities or cerebral microbleed burden were found amongst 624 participants.

**Conclusions** Lack of association between two Alzheimer's disease susceptibility gene loci and markers of cerebral small vessel disease may reflect the relative health of this population compared with those in other studies in the literature.

Key words: brain microbleeds, epidemiology, MRI, neurology, risk factors, vascular events

Correspondence: Joanna M. Wardlaw\*, Brain Research Imaging Centre, Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh EH4 2XU, UK.

E-mail: Joanna.Wardlaw@ed.ac.uk

<sup>1</sup>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

<sup>2</sup>Brain Research Imaging Centre, Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK

<sup>3</sup>Department of Psychology, University of Edinburgh, Edinburgh, UK

<sup>4</sup>Medical Genetics Section, University of Edinburgh Centre for Genomics and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK

<sup>5</sup>Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Department of Neuroimaging Sciences, The University of Edinburgh, Edinburgh, UK

<sup>6</sup>Joseph & Kathleen Bryan Alzheimer's Disease Research Center, Department of Neurology, Duke University Medical Center, Durham, NC, USA

<sup>7</sup>Zinfandel Pharmaceuticals, Inc., Durham, NC, USA

<sup>8</sup>Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

Received: 11 August 2014; Accepted: 30 June 2015; Published online 26 August 2015

**Conflict of interest:** Allen D Roses is the CEO and only stock holder of Zinfandel Pharmaceuticals, a company in an Alliance with Takeda Pharmaceuticals, to perform the prospective qualification of the *TOMM40* marker for age of onset distribution of Alzheimer's Disease. For this study, Zinfandel Pharmaceuticals paid for the *TOMM40* assays to be performed for medical research, not as a clinical diagnostic. AMS is the spouse of ADR, and AMS and MWL are consultants to Zinfandel Pharmaceuticals.

**Funding:** LBC1936 data collection was supported by the Disconnected Mind project (<http://disconnectedmind.ed.ac.uk>) funded by Age UK. J. M. W. is part-funded by the Scottish Funding Council as part of the SINAPSE Collaboration (<http://www.sinapse.ac.uk>). Funding from the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC), and MRC is gratefully acknowledged.

DOI: 10.1111/ijis.12615

### **Introduction**

There is evidence that the presence of cardiovascular disease pathology can increase the future risk of Alzheimer's disease (AD) and cognitive decline (1). White matter hyperintensities (WMH) and cerebral microbleeds (CMB) are generally considered to reflect cerebrovascular burden in ageing. They are manifestations and markers of cerebral small-vessel disease and often co-occur (2).

The mechanisms underlying significant association between cardiovascular and neurodegenerative pathology are unclear; however, there are three main hypotheses (1). Firstly, it is possible that cardiovascular diseases and AD/cognitive decline share common risk factors and are not mechanistically related (1). Secondly, it is possible that cardiovascular burden may expedite progression of AD/cognitive decline through promoting atherosclerosis and accumulations of amyloid-beta plaques, and/or (thirdly) by increasing vulnerability to such pathology and lowering the threshold at which cognitive decline becomes apparent behaviorally, even in the absence of a mechanistic link (1,3).

Two genetic risk factors for AD and age-related cognitive decline are in the *APOE* and *TOMM40* gene loci (4). Two recent meta-analyses reported no overall significant association between *APOE*  $\epsilon 4$  and WMH in older adults ( $P > 0.05$ ). Paternoster *et al.* (5) did not stratify analyses by whether participants were generally healthy or not (total  $n = 8546$ ), whereas Schilling *et al.* (6) did ('healthy'  $n = 8405$ ). However, these reports were not independent because some common data were included in both. In contrast, two meta-analyses reported a significant association between *APOE*  $\epsilon 4$  and CMB: Schilling *et al.* (6) ('healthy'  $n = 5387$ ;  $P = 0.002$ ) and Maxwell *et al.* (7) (total  $n = 7351$ ;  $P < 0.01$ ). These two reports also had a degree of overlapping datasets. A more recent individual study (8) reported similar results ( $n = 1965$ ,  $P < 0.05$ ).

In the above reports, the positive association between *APOE*  $\epsilon 4$  and CMB burden was not completely consistent; other genetic predictor variables may exert independent effects. The *TOMM40* rs10524523 ('523') variable length poly-T repeat has been significantly associated with brain phenotypes such as cognitive decline,

independent of *APOE* genotype (9). The *TOMM40* 523 locus is characterized by a variable number of T residues (poly-T repeats) that can be grouped into 'short' (<20; 'S'), 'long' (20–29; 'L'), and 'very long' ( $\geq 30$ ; 'VL') (10). Roses (11) plotted histograms showing the distributions of poly-T repeat lengths in different *APOE* genotypes:  $\epsilon 3/\epsilon 3$ ,  $\epsilon 3/\epsilon 4$ , and  $\epsilon 4/\epsilon 4$ . The poly-T repeat was strongly linked with the *APOE*  $\epsilon$  haplotype;  $\epsilon 4$  is linked to L, with  $\epsilon 3$  linked to either S or VL alleles (4); investigating the effects of *TOMM40* 523 genotype on brain-related phenotypes may explain some of the heterogeneity in the possible *APOE*  $\epsilon 4$  and WMH/CMB association. This study therefore aims to contribute a large amount of relevant genetic *APOE/TOMM40* and WMH/CMB brain imaging data, from a sample of community-dwelling older adults.

## Methods

### Sample and genotyping

The Lothian Birth Cohort 1936 (LBC1936) is a longitudinal sample of generally healthy community-dwelling older adults (12). All participants were born in 1936, and most resided in the Edinburgh area of Scotland in older age. The sample received detailed cognitive, medical, and demographic assessments at the Wellcome Trust Clinical Research Facility (Edinburgh; <http://www.wtcrf.ed.ac.uk>) at age  $\sim 73$  years. Participants underwent detailed brain MRI around the same time (13) (mean interval = 65.0 days, SD = 39.5). Of the 866 LBC1936 participants that attended clinic assessment, 700 completed neuroimaging (mean age = 72.70, SD = 0.7). Details of LBC1936 recruitment and assessment, including aspects of possible selection bias and attrition, can be found in two cohort protocol papers by Deary *et al.* (12,14).

Participants were genotyped by TaqMan assay for *APOE*  $\epsilon$  (Applied Biosystems, Carlsbad, CA, USA) using DNA isolated from whole blood (12). *TOMM40* 523 was genotyped by the laboratory of Dr. Ornit Chiba-Falek (Duke University) as described previously (15).

### Brain MRI

Participants underwent whole brain structural MRI, acquired using a GE Signa Horizon 1.5 T HDxt clinical scanner (General Electric, Milwaukee, WI, USA) equipped with a self-shielding gradient set (33 mT/m maximum gradient strength) and manufacturer-supplied eight-channel phased-array head coil, lasting around 70 min. In addition to standard structural T2-, T2\*-, and FLAIR-weighted MRI, the imaging protocol included a high-resolution T1-weighted volume sequence acquired in the coronal plane with field-of-view of  $256 \times 256$  mm, imaging matrix  $192 \times 192$  (zero-filled to  $256 \times 256$ ), 160 1.3-mm thick slices giving  $1 \times 1 \times 1.3$ -mm voxel dimensions (13). The repetition, echo, and inversion times were 10, 4, and 500 ms respectively. The detailed protocol for WMH/CMB image processing, and intracranial/total brain volume measurement, is published by Wardlaw *et al.* (13). WMH volumes were calculated from binary masks generated by an in-house-developed and validated software tool written in MATLAB that applies a technique named Multispectral Colouring Modulation and Variance Identification:

1936 [MCMxxxVI (16)]. Visual scoring of WMH was also performed using the Fazekas scale by experienced neuroradiologists.

Microhemorrhages (i.e. CMBs) were coded for number and distribution using a simplified version of the Brain Observer MicroBleed Scale [BOMBS (17)], which considers microbleeds as small homogenous round foci of low signal intensity on T2\*-weighted images, of less than 10 mm in diameter. This rating scale is used to record the number of observed definite or possible microbleeds in the right/left hemispheres, delineated into bleeds <5 mm and 5–10 mm. Because of the relatively low frequency of CMB's in the LBC1936 sample, we examined the presence of  $\geq 1$  definite/possible microbleeds, strictly lobar microbleeds, strictly deep or infratentorial microbleeds. Any significant findings were reanalyzed as definite microbleeds only.

Inter- and intra-rater reliability standards have been reported in previous work (13). Genotyping was performed blind to imaging (and vice versa). Imaging lesions were defined according to STRIVE recommendations (2). Of the 700 participants that completed brain MRI, 25 had one or more lacunar infarcts, and given this low frequency, we did not consider this variable further.

### Statistical analysis

Age in days and gender were included as covariates. An online calculator was used to perform tests of Hardy–Weinberg equilibrium and determine minor allele frequencies (<http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-3-alleles.html>). Volumetric WMH data were transformed with a natural logarithmic function to provide a more normal distribution. Data were analyzed with the IBM SPSS statistics program (version 17; IBM, Armonk, NY, USA).

Univariate general linear models tested the effects of separate *APOE* and *TOMM40* genotypes upon imaging variables. Specifically, the effects of *APOE*  $\epsilon 4$  'risk' allele presence vs. absence (i.e.  $\epsilon 2/\epsilon 4$ ;  $\epsilon 3/\epsilon 4$ ;  $\epsilon 4/\epsilon 4$  vs.  $\epsilon 2/\epsilon 2$ ;  $\epsilon 2/\epsilon 3$ ;  $\epsilon 3/\epsilon 3$ ) were tested. To assess the independent effects of *TOMM40* 523 genotype, we tested for effects of S allele frequency vs. pooled L/VL alleles (simply L\*; S/S vs. S/L\* vs. L\*/L\*) in participants with the 'neutral' *APOE*  $\epsilon 3/\epsilon 3$  genotype (9) and then in the  $\epsilon 3/\epsilon 4$  genotype subgroup, because *TOMM40* 523 genotype may interact with the  $\epsilon 4$  allele (18).

## Results

Of the 866 LBC1936 participants that attended clinic assessment, 700 completed neuroimaging. Participants were excluded from analysis if they had Mini-Mental State Exam scores below 24 or had not completed the test (19). [A cutoff of 24 was used because this is considered the lowest possible score within the range of 'no cognitive impairment', and is a common approach (20)]. This left 694 participants, of whom 624 and 636 had successful genotyping for *APOE*  $\epsilon$  and *TOMM40* 523, respectively. Allele frequencies were in Hardy–Weinberg equilibrium for *APOE* ( $\epsilon 2 = 7.4\%$ ,  $\epsilon 3 = 77.0\%$ ;  $\epsilon 4 = 15.6\%$ ) and *TOMM40* (S = 40.9%, L = 15.3%, and VL = 43.9%; both  $P > 0.05$ ). Allele frequencies are shown in Table S1.

There were no significant associations between *APOE*  $\epsilon 4$  presence (vs. absence), or *TOMM40* 523 genotype (in any analyses), and WMH/CMB variables (all  $P > 0.05$ ; Tables S2–S3).

## Discussion

Our findings align with previous meta-analyses in observing no significant *APOE*/WMH association (5,6). In terms of CMB, this report does not align with recent meta-analyses that concluded significant deleterious effects of *APOE*  $\epsilon 4$  (6,7). Of those meta-analyses, Schilling *et al.* (6) observed a significant effect of *APOE*  $\epsilon 4$  in general populations only – and not in pooled samples with neurological or vascular disorders; the lack of association in LBC1936 may be because of the relatively good health of the sample. Our findings do align with two individual studies of generally healthy older adults (included in the meta-analyses) which reported no significant *APOE*  $\epsilon 4$  present (vs. absent) effects [by Sveinbjornsdottir *et al.* (21) ( $n = 1725$ ) and Jeerakathil *et al.* (22) ( $n = 368$ )]. There was no evidence of an independent effect of *TOMM40* 523 genotype here.

Previous significant associations in individual CMB reports may perhaps reflect a degree of type 1 error, particularly in smaller samples. Several studies report broader age ranges than examined here (71–74 years;  $SD = 0.7$ ) (7). Any effect of age on CMB may be via processes associated with age; controlling for age statistically is unlikely to completely eradicate these effects (23), so wide age ranges could possibly contribute to spurious genetic associations.

The BOMBS instrument allows raters to note CMBs as either definite or possible [a cautious category to avoid misclassifications of mimics (17)]. It would be interesting to examine if previously reported significant *APOE*-CMB associations are affected when analyzed to incorporate possible microbleeds/mimics.

It is possible that the sample size examined here is not sufficiently powered to detect any possibly modest effects of *APOE* or *TOMM40* genotypes on WMH/CMB (5). It is possible that the LBC1936 sample is generally healthier when compared with other samples, exacerbated by a selection bias where healthier participants were more likely to attend brain MRI assessment (24). Generally, the LBC1936 sample is slightly restricted in range towards the upper end of general mental ability and socioeconomic status (14). In addition, *APOE*  $\epsilon 4$  genotype has previously been associated with earlier mortality and cardiovascular disease (25); it is possible that a selection bias exists whereby healthier participants are more likely to attend cognitive or brain imaging assessment, and this may contribute to our finding no effect of *APOE*/*TOMM40* genotypes on WMH/CMB phenotypes with MRI.

Maxwell *et al.* (7) estimated with a ‘fail-safe N calculation’ that null studies including at least 7700 participants would be required to attenuate their meta-analysis *APOE*  $\epsilon 4$ /CMB association (reported  $P = 0.01$ ) to non-significance (i.e.  $P > 0.05$ ). Further independent studies will help to define the more exact nature and strength of any *APOE*/CMB association in generally healthy populations.

## Acknowledgements

The participation of LBC1936 members is gratefully acknowledged. The work was undertaken within the University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (<http://www.ccace.ed.ac.uk>), part of the cross-council Lifelong Health and Wellbeing Initiative (G0700704/84698).

## Authors' contributions

Designed the experiments: D. M. L., J. M. W., D. J. P., I. J. D. Analyzed the data/wrote the manuscript: D. M. L. Interpreted the results, critically revised content, and approved the final version: All authors.

## References

- Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. *J Intern Med* 2006; **260**:211–23.
- Wardlaw JM, Smith EE, Biessels GJ *et al.* Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; **12**:822–38.
- Brickman AM, Siedlecki KL, Muraskin J *et al.* White matter hyperintensities and cognition: Testing the reserve hypothesis. *Neurobiol Aging* 2011; **32**:1588–98.
- Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK. *TOMM40* and *APOE*: requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. *Alzheimers Dement* 2013; **9**:132–6.
- Paternoster L, Chen W, Sudlow CLM. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. *Stroke* 2009; **40**:2020–6.
- Schilling S, DeStefano AL, Sachdev PS *et al.* *APOE* genotype and MRI markers of cerebrovascular disease. *Neurology* 2013; **81**:292–300.
- Maxwell SS, Jackson CA, Paternoster L *et al.* Genetic associations with brain microbleeds Systematic review and meta-analyses. *Neurology* 2011; **77**:158–67.
- Romero JR, Preis SR, Beiser A *et al.* Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. *Stroke* 2014; **45**:1492–4.
- Caselli RJ, Dueck AC, Huentelman MJ *et al.* Longitudinal modeling of cognitive aging and the *TOMM40* effect. *Alzheimers Dement* 2012; **8**:490–5.
- Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Genetic variation at a single locus and age of onset for Alzheimer's disease. *Alzheimers Dement* 2010; **6**:125–31.
- Roses AD. An inherited variable poly-T repeat genotype in *TOMM40* in Alzheimer disease. *Arch Neurol* 2010; **67**:536–41.
- Deary IJ, Gow AJ, Taylor MD *et al.* The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC Geriatr* 2007; **7**:28.
- Wardlaw JM, Bastin ME, Valdés Hernández MC *et al.* Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol. *Int J Stroke* 2011; **6**:547–59.
- Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort profile: the Lothian birth cohorts of 1921 and 1936. *Int J Epidemiol* 2012; **41**:1576–84.
- Linnertz C, Saunders AM, Lutz MW *et al.* Characterization of the poly-t variant in the *tomm40* gene in diverse populations. *PLoS ONE* 2012; **7**:e30994.
- Valdés Hernández MDC, Ferguson KJ, Chappell FM, Wardlaw JM. New multispectral MRI data fusion technique for white matter lesion segmentation: method and comparison with thresholding in FLAIR images. *Eur Radiol* 2010; **20**:1684–91.

- 17 Cordonnier C, Potter GM, Jackson CA *et al.* Improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). *Stroke* 2009; **40**:94–9.
- 18 Bruno D, Nierenberg JJ, Ritchie JC, Lutz MW, Pomara N. Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. *Psychoneuroendocrinology* 2012; **37**:366–71.
- 19 Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. *J Psychiatr Res* 1975; **12**:189–98.
- 20 Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. *J Am Geriatr Soc* 1992; **40**:922–35.
- 21 Sveinbjornsdottir S, Sigurdsson S, Aspelund T *et al.* Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. *J Neurol Neurosurg Psychiatry* 2008; **79**:1002–6.
- 22 Jeerakathil T, Wolf PA, Beiser A *et al.* Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. *Stroke* 2004; **35**:1831–5.
- 23 Hofer SM, Sliwinski MJ. Understanding ageing: an evaluation of research designs for assessing the interdependence of ageing-related changes. *Gerontology* 2001; **47**:341–52.
- 24 Lyall DM, Lopez LM, Bastin ME *et al.* ADRB2, brain white matter integrity and cognitive ageing in the Lothian Birth Cohort 1936. *Behav Genet* 2013; **43**:13–23.
- 25 Rosvall L, Rizzuto D, Wang HX, Winblad B, Graff C, Fratiglioni L. APOE-related mortality: effect of dementia, cardiovascular disease and gender. *Neurobiol Aging* 2009; **30**:1545–51.

### Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

**Table S1.** Frequency statistics for *APOE/TOMM40* poly-T repeat genotypes.

**Table S2.** *APOE/TOMM40* genotypes and white matter hyperintensities/cerebral microbleeds: association statistics.

**Table S3.** *TOMM40* genotypes and white matter hyperintensities/cerebral microbleeds in *APOE* subgroups: association statistics.